PMOS

PCOS? No Here is the New Name of so Common multisystem Syndrome Renamed in 2026

Polycystic Ovary Syndrome (PCOS / PCOD) — High-Yield Notes

Based on international evidence-based guidelines, Endocrine Society, ACOG, and peer-reviewed literature. (NCBI)


Definition

  • PCOS = common endocrine-metabolic disorder in reproductive-age women
  • Characterized by:
    • Hyperandrogenism
    • Ovulatory dysfunction
    • Polycystic ovarian morphology
  • Associated with:
    • Insulin resistance
    • Obesity
    • Infertility
    • Metabolic syndrome

Etiopathogenesis

Multifactorial Disorder

  • Genetic predisposition
  • Environmental factors
  • Hormonal dysregulation
  • Insulin resistance

Core Pathophysiology

1. Increased LH secretion

  • ↑ GnRH pulse frequency → preferential LH secretion
  • ↑ LH stimulates theca cells
  • ↑ androgen production

2. Insulin resistance

  • Present in many patients (even lean PCOS)
  • Hyperinsulinemia:
    • Stimulates ovarian androgen synthesis
    • Suppresses SHBG production in liver
    • ↑ free testosterone

3. Follicular arrest

  • Failure of dominant follicle maturation
  • Multiple immature follicles accumulate

4. Hyperandrogenism

  • Causes:
    • Hirsutism
    • Acne
    • Alopecia
    • Menstrual irregularity

Diagnostic Criteria (Rotterdam Criteria)

Diagnosis requires 2 out of 3 after excluding other causes: (NCBI)

A. Ovulatory Dysfunction

  • Oligomenorrhea
  • Amenorrhea
  • Anovulation

Menstrual abnormalities

  • Cycle >35 days
  • <8 cycles/year

B. Hyperandrogenism

Clinical

  • Hirsutism
  • Acne
  • Androgenic alopecia

Biochemical

  • ↑ Total testosterone
  • ↑ Free testosterone
  • ↑ DHEAS

C. Polycystic Ovarian Morphology (USG)

  • ≥20 follicles per ovary OR
  • Ovarian volume >10 mL

Classic appearance

  • “String of pearls”

Important Diagnostic Point


Differential Diagnoses to Exclude

Endocrine causes

  • Hypothyroidism
  • Hyperprolactinemia
  • Cushing syndrome
  • Congenital adrenal hyperplasia
  • Androgen-secreting tumors

Others

  • Acromegaly
  • Premature ovarian insufficiency

Clinical Features

Menstrual

  • Oligomenorrhea
  • Amenorrhea
  • Irregular cycles
  • Infertility

Hyperandrogenic Features

  • Hirsutism
  • Acne
  • Alopecia
  • Seborrhea

Metabolic Features

  • Obesity
  • Central obesity
  • Insulin resistance
  • Acanthosis nigricans

Reproductive Features

  • Subfertility/infertility
  • Recurrent miscarriage

Psychological Associations

  • Anxiety
  • Depression
  • Eating disorders
  • Poor body image

Investigations

Hormonal Tests

  • Total/free testosterone
  • DHEAS
  • LH, FSH
  • Prolactin
  • TSH
  • 17-hydroxyprogesterone

Metabolic Screening

  • Fasting glucose
  • HbA1c
  • Lipid profile
  • OGTT (high-risk patients)

Imaging

  • Pelvic ultrasonography

Typical Laboratory Findings

  • ↑ LH:FSH ratio (>2:1 sometimes)
  • ↑ Testosterone
  • ↑ Insulin
  • ↓ SHBG

Complications

Reproductive

  • Infertility
  • Anovulation
  • Pregnancy complications

Metabolic

  • Type 2 diabetes mellitus
  • Dyslipidemia
  • Metabolic syndrome
  • Hypertension

Cardiovascular

  • Increased long-term CV risk

Endometrial

  • Endometrial hyperplasia
  • Endometrial carcinoma
    • Due to chronic unopposed estrogen

Management

1. Lifestyle Modification (First-line)

  • Weight reduction
  • Exercise
  • Calorie restriction
  • Low glycemic diet

Benefits

  • Improves ovulation
  • Reduces insulin resistance
  • Improves fertility

2. Menstrual Irregularity Management

Combined Oral Contraceptive Pills (COCPs)

  • First-line for nonfertility symptoms
  • Benefits:
    • Regular cycles
    • ↓ androgen production
    • Improves acne/hirsutism

3. Hirsutism & Acne

Antiandrogens

  • Spironolactone
  • Finasteride
  • Flutamide (rare due to hepatotoxicity)

Important

  • Use contraception with antiandrogens

4. Insulin Resistance

Metformin

  • Improves insulin sensitivity
  • May restore ovulation
  • Useful in:
    • Obesity
    • Prediabetes
    • Metabolic syndrome

5. Infertility Treatment

First-line Ovulation Induction

  • Letrozole (preferred)
  • Clomiphene citrate

Others

  • Gonadotropins
  • IVF if resistant

Pregnancy Risks in PCOS

  • Gestational diabetes
  • Pregnancy-induced hypertension
  • Preeclampsia
  • Preterm birth

Adolescent PCOS

  • Diagnosis difficult soon after menarche
  • Physiologic irregular cycles common
  • Ultrasound less reliable in adolescents (NCBI)

High-Yield Exam Pearls

  • Most accepted criteria = Rotterdam criteria
  • Need 2 out of 3 criteria
  • PCOS is a diagnosis of exclusion
  • Most common cause of anovulatory infertility
  • Insulin resistance is central mechanism
  • Chronic anovulation → unopposed estrogen → endometrial cancer risk
  • First-line treatment = lifestyle modification
  • First-line ovulation induction = letrozole
  • COCPs are first-line for menstrual symptoms
  • “String of pearls” appearance on USG

Very Short Summary

PCOS is a common endocrine disorder characterized by:

  • Hyperandrogenism
  • Irregular ovulation
  • Polycystic ovaries

Main problems:

  • Irregular periods
  • Infertility
  • Hirsutism
  • Obesity
  • Insulin resistance

Treatment:

  • Lifestyle change
  • COCPs
  • Metformin
  • Letrozole for fertility

Renaming PCOS to PMOS

Yes — there has been a major recent international change in terminology.

New Name for PCOS

The condition previously called PCOS (Polycystic Ovary Syndrome) has officially been renamed:

PMOS

Polyendocrine Metabolic Ovarian Syndrome

This was announced in 2026 after a 14-year international consensus effort involving:

  • Endocrinologists
  • Gynecologists
  • Researchers
  • Patient advocacy groups
  • More than 50 global medical organizations (The Guardian)

Why Was the Name Changed?

Experts felt the term “PCOS” was misleading because:

  • Many patients do not actually have ovarian cysts
  • The disorder affects multiple body systems, not only ovaries
  • The old name caused:
    • Delayed diagnosis
    • Confusion
    • Stigma
    • Under-recognition of metabolic disease

The new term “PMOS” better reflects:

  • Endocrine dysfunction
  • Metabolic abnormalities
  • Hormonal imbalance
  • Reproductive effects (The Guardian)

Full Form Breakdown

P — Polyendocrine

Multiple hormone systems are involved

M — Metabolic

Strong association with:

  • Insulin resistance
  • Obesity
  • Diabetes
  • Dyslipidemia

O — Ovarian

Ovarian dysfunction and ovulatory problems remain important

S — Syndrome

Collection of related clinical features


Important Clinical Point

Diagnostic criteria remain essentially the same.

The name changed, but the underlying disorder and diagnostic approach remain based on established international criteria. (The Cut)


Key Facts

  • Affects approximately 1 in 8 women worldwide
  • Estimated >170 million affected globally
  • Strongly associated with:
    • Infertility
    • Metabolic syndrome
    • Type 2 diabetes
    • Cardiovascular risk
    • Mental health disorders (endocrine.org)

Transition Timeline

International organizations plan gradual adoption of the term PMOS in:

  • Clinical guidelines
  • Research papers
  • Medical education
  • Public awareness campaigns

Implementation is expected over the next few years. (The Guardian)

Leave a Comment

Your email address will not be published. Required fields are marked *

[instagram-feed]
UTI complete slides